Literature DB >> 22090514

Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.

Hiroyasu Sato1, Shigeki Arawaka, Susumu Hara, Shingo Fukushima, Kaori Koga, Shingo Koyama, Takeo Kato.   

Abstract

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra (SN) and the appearance of fibrillar aggregates of insoluble α-synuclein (α-syn) called Lewy bodies (LBs). Approximately 90% of α-syn deposited in LBs is phosphorylated at serine 129 (Ser129). In contrast, only 4% of total α-syn is phosphorylated in normal brain, suggesting that accumulation of Ser129-phosphorylated α-syn is involved in the pathogenesis of PD. However, the role of Ser129 phosphorylation in α-syn neurotoxicity remains unclear. In this study, we coexpressed familial PD-linked A53T α-syn and G-protein-coupled receptor kinase 6 (GRK6) in the rat SN pars compacta using recombinant adeno-associated virus 2. Coexpression of these proteins yielded abundant Ser129-phosphorylated α-syn and significantly exacerbated degeneration of dopaminergic neurons when compared with coexpression of A53T α-syn and GFP. Immunohistochemical analysis revealed that Ser129-phosphorylated α-syn was preferentially distributed to swollen neurites. However, biochemical analysis showed that the increased expression of Ser129-phosphorylated α-syn did not promote accumulation of detergent-insoluble α-syn. Coexpression of catalytically inactive K215R mutant GRK6 failed to accelerate A53T α-syn-induced degeneration. Furthermore, introducing a phosphorylation-incompetent mutation, S129A, into A53T α-syn did not alter the pace of degeneration, even when GRK6 was coexpressed. Our study demonstrates that authentically Ser129-phosphorylated α-syn accelerates A53T α-syn neurotoxicity without the formation of detergent-insoluble α-syn, and suggests that the degenerative process could be constrained by inhibiting the kinase that phosphorylates α-syn at Ser129.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22090514      PMCID: PMC6633319          DOI: 10.1523/JNEUROSCI.3967-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

1.  Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events.

Authors:  Neeraj Singh; Vivek Lawana; Jie Luo; Phang Phong; Ahmed Abdalla; Bharathi Palanisamy; Dharmin Rokad; Souvarish Sarkar; Huajun Jin; Vellareddy Anantharam; Anumantha G Kanthasamy; Arthi Kanthasamy
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

2.  Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.

Authors:  Lih-Fen Lue; Douglas G Walker; Charles H Adler; Holly Shill; Hung Tran; Haruhiko Akiyama; Lucia I Sue; John Caviness; Marwan N Sabbagh; Thomas G Beach
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

Review 3.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 4.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Authors:  Benjamin Dehay; Mathieu Bourdenx; Philippe Gorry; Serge Przedborski; Miquel Vila; Stephane Hunot; Andrew Singleton; C Warren Olanow; Kalpana M Merchant; Erwan Bezard; Gregory A Petsko; Wassilios G Meissner
Journal:  Lancet Neurol       Date:  2015-06-03       Impact factor: 44.182

5.  Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.

Authors:  Md Shariful Islam; Hendrik Nolte; Wright Jacob; Anna B Ziegler; Stefanie Pütz; Yael Grosjean; Karolina Szczepanowska; Aleksandra Trifunovic; Thomas Braun; Hermann Heumann; Rolf Heumann; Bernhard Hovemann; Darren J Moore; Marcus Krüger
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

Review 6.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

7.  Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.

Authors:  Douglas G Walker; Lih-Fen Lue; Charles H Adler; Holly A Shill; John N Caviness; Marwan N Sabbagh; Haruhiko Akiyama; Geidy E Serrano; Lucia I Sue; Thomas G Beach
Journal:  Exp Neurol       Date:  2012-11-28       Impact factor: 5.330

Review 8.  Sumoylation in neurodegenerative diseases.

Authors:  Petranka Krumova; Jochen H Weishaupt
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

9.  The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.

Authors:  Mohamed-Bilal Fares; Nadine Ait-Bouziad; Igor Dikiy; Martial K Mbefo; Ana Jovičić; Aoife Kiely; Janice L Holton; Seung-Jae Lee; Aaron D Gitler; David Eliezer; Hilal A Lashuel
Journal:  Hum Mol Genet       Date:  2014-04-11       Impact factor: 6.150

Review 10.  Alpha-Synuclein as a Biomarker for Parkinson's Disease.

Authors:  Anzari Atik; Tessandra Stewart; Jing Zhang
Journal:  Brain Pathol       Date:  2016-05       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.